Pomdoctor Limited announced a series of new, deeper collaborations with four leading domestic pharmaceutical companies—Jiangsu Haosoh Pharmaceutical Group, Xiamen Amoytop Biotech, Shenyang Sinqi Pharmaceutical, and Eddingpharm (Suzhou). The agreements give Pomdoctor preferential purchase discounts, rebates, and sales incentives that are tied to revenue targets, allowing the company to secure branded products at lower cost and with greater supply stability.
The move is part of Pomdoctor’s strategy to strengthen its internet‑hospital platform, which focuses on chronic‑disease management. By cutting out intermediaries, the company can offer physicians and patients a broader range of patented treatments while improving pricing power. The new supply‑chain network is expected to help Pomdoctor capture a larger share of China’s rapidly expanding online drug‑sales market, which grew from RMB 19 billion in 2020 to RMB 71.8 billion in 2024—a compound annual growth rate of 39.4%.
Pomdoctor’s financial performance remains a concern. For the six months ended June 30 2025, the company reported net revenue of RMB 174.5 million (US$24.4 million) and a net loss of RMB 19.9 million (US$2.8 million). Online‑pharmacy and internet‑hospital sales rose 83.2% year‑over‑year, driven by strong demand for chronic‑disease products. Earlier results show losses of RMB 37.4 million in 2024 and RMB 36.9 million in 2023, with total assets falling short of liabilities, leaving the company with negative equity. The IPO in October 2025 raised only about $20 million, below the $25 million minimum required by Nasdaq’s new listing rules, underscoring the company’s limited cash resources.
Management highlighted the strategic importance of the new partnerships. Chairman and CEO Zhenyang Shi said, “China’s rapidly expanding online pharmaceutical sales market offers significant development opportunities.” He added, “Our flexible collaboration models create win‑win outcomes for both POMDOCTOR and our pharmaceutical partners by effectively integrating the strengths of each party in a cost‑efficient manner.” Shi also expressed optimism that the supply‑chain collaboration model would become a key driver of modern pharmaceutical distribution and a catalyst for reshaping the traditional supply chain.
The partnerships are expected to provide a competitive edge against larger ecosystem players such as Ping An Health and JD Health. Direct sourcing from branded manufacturers should reduce procurement costs, improve product quality, and enhance supply reliability—factors that can translate into higher margins and stronger market positioning. However, the company’s ongoing financial instability and persistent losses suggest that the partnership gains will need to be carefully managed to avoid further erosion of profitability.
The announcement signals Pomdoctor’s intent to deepen its core capabilities while navigating a challenging financial environment. Investors will likely weigh the potential for improved pricing and supply stability against the company’s high risk profile and negative equity, which could limit its ability to invest in growth initiatives.
The article provides a comprehensive view of the partnership expansion, its strategic rationale, and the financial context that frames Pomdoctor’s future prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.